ERBB2 and breast cancer: In another just published study,25 the median PFS and OS were 8.67 and 13.93 months, respectively in the 39 HER2‐positive breast cancer patients with brain metastases, and they also confirmed the prolonged survival of combined therapy of pyrotinib with surgery or radiation in these patients.